personalized medicine
Breast Cancer Therapy Response Predicted by Multiomic Machine Learning Model
A team led by researchers at the University of Cambridge analyzed more than 160 pre-treatment tumor biopsies to identify features linked to treatment response.
Redx Pharma, Caris Life Sciences Partner for Colorectal Cancer Phase II Drug Study Recruitment
The pharma firm is using Caris’ comprehensive molecular profiling to help advance its investigational Porcupine inhibitor, RXC004, in the US.
GE Healthcare, University of Cambridge Team on AI-Based Precision Oncology
Building on earlier work supported by the Mark Foundation for Cancer Research and Cancer Research UK, the partners will create an app to aggregate and analyze clinical, genomic, and imaging data.
HER2 Treatments See New Milestones in Colorectal Cancer, With Liquid Biopsy Identifying Responders
Premium
New data from a Japanese Phase II study have solidified a path forward for pertuzumab plus trastuzumab in HER2-positive colorectal cancer patients.
Local Cancer Genomic Profiling Options Grow, Though Central Labs Will Likely Keep Major Role
Premium
As economic and practical challenges of next-gen sequencing have eased in recent years, more groups are bringing comprehensive cancer genomic testing in house.